---
title: "Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295819689.md"
description: "Kura Oncology's 12-month price target was raised to $32, implying a 222% upside from the Aug. 12 close. The average analyst estimate increased slightly to $31.83, with forecasts ranging from $15 to $76. Consensus remains 'Buy' among 15 covering analysts."
datetime: "2026-08-13T15:20:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295819689.md)
  - [en](https://longbridge.com/en/news/295819689.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295819689.md)
generator: "portal-rs"
---

# Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside

-   According to estimates from 12 analysts, Kura Oncology, Inc. stock's average price target has risen from $31.17 to $31.83, with forecasts ranging from $15 to $76 per share
-   Based on the Aug. 12 closing price, the updated target implies approximately 220% potential upside
-   Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Kura Oncology, Inc. on the , and track all previous and future analyst recommendations for Kura Oncology, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Kura Oncology CFO Jennifer Fulk files initial beneficial ownership statement](https://longbridge.com/en/news/298640802.md)
- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)
- [Apnimed, Inc. reports Q2 results](https://longbridge.com/en/news/298366495.md)
- [Kura Oncology names Jennifer Fulk chief financial officer](https://longbridge.com/en/news/298307125.md)
- [Kura Oncology launches Caspian Therapeutics, targets clinical proof-of-concept for diabetes drug KO-7246 after USD 50 million financing](https://longbridge.com/en/news/298445580.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**